Skip to main content
IMMUNOLOGY2026™ Main banner
Final Program


Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.

  1. Home

  • Thursday, Apr 16th
    12:45 PM - 1:00 PM US ET
    Personalized Tumor Membrane Vesicle Vaccine Immunotherapy for Head and Neck Squamous Cell Carcinoma (HNSCC)
    Location: 102
    Author: Ramireddy Bommireddy – Emory University
    Vaccines and Immunotherapy (VAC)
  • Thursday, Apr 16th
    12:45 PM - 2:15 PM US ET
    VAC1 - Learning about Human Immune Responses from Vaccination and Immunotherapy
    Location: 102
    Moderator: Ramireddy Bommireddy – Emory University
    Moderator: Catarina Hioe – Icahn School of Medicine, Mount Sinai
    Vaccines and Immunotherapy (VAC)
  • Thursday, Apr 16th
    1:00 PM - 1:15 PM US ET
    Bivalent vaccination fails to enhance conserved spike T cell responses across BetaCoronaviruses
    Location: 102
    Author: Ziyin Wang, PhD – La Jolla Inst. for Immunol.
    Vaccines and Immunotherapy (VAC)
  • Thursday, Apr 16th
    1:30 PM - 1:45 PM US ET
    Whooping cough disease induces durable protection from asymptomatic re-infection
    Location: 102
    Author: Emil Johansson, PhD – La Jolla Institute for Immunology
    Vaccines and Immunotherapy (VAC)
  • Thursday, Apr 16th
    1:45 PM - 2:00 PM US ET
    Differential effect of Recombinant Zoster Vaccine (RZV) and Zoster Vaccine Live (ZVL) in a controlled human infection model (CHIM) of VZV reactivation
    Location: 102
    Author: Adriana Weinberg, MD – University of Colorado Anschutz Medical Campus
    Vaccines and Immunotherapy (VAC)
  • Thursday, Apr 16th
    2:00 PM - 2:15 PM US ET
    Impaired B Cell and cTfh Immune Pathways Underlie Influenza Vaccine Hyporesponsiveness in Older, Frail, and Multimorbid Adults
    Location: 102
    Author: Joseph Kass – Case Western Reserve University
    Vaccines and Immunotherapy (VAC)
  • Thursday, Apr 16th
    3:45 PM - 4:00 PM US ET
    GLUT1 in Memory CD4+ T-cells Correlates with Sustained Antibody Responses and Polyfunctionality Post-RSV Vaccination in Immunocompromised Individuals
    Location: 102
    Author: Nirvani P. Jairam, BS – Johns Hopkins Univ. Sch. of Med.
    Vaccines and Immunotherapy (VAC)
  • Thursday, Apr 16th
    4:00 PM - 4:15 PM US ET
    Processing-Optimized Multi-Epitope mRNA Vaccine Enhances HIV-1–Specific CD8⁺ T Cells
    Location: 102
    Author: Takuto Nogimori, PhD (he/him/his) – National Institutes of Biomedical Innovation, Health and Nutrition
    Vaccines and Immunotherapy (VAC)
  • Thursday, Apr 16th
    4:15 PM - 4:30 PM US ET
    Toward a Pan-Arenavirus T-cell Vaccine: Identification and Preclinical Evaluation of Conserved Epitope constructs
    Location: 102
    Author: Ziyin Wang, PhD – La Jolla Inst. for Immunol.
    Vaccines and Immunotherapy (VAC)
  • Thursday, Apr 16th
    4:30 PM - 4:45 PM US ET
    Development of T-cell-based immunotherapy against chronic Hepatitis B infection
    Location: 102
    Author: Sofiya Yusova, MS (she/her/hers) – OHSU Oregon National Primate Research Center
    Vaccines and Immunotherapy (VAC)
  • Thursday, Apr 16th
    4:45 PM - 5:00 PM US ET
    An HIV V1V2 mRNA-LNP vaccine induces strong, cross-clade functional antibody responses in mice and rhesus macaques
    Location: 102
    Author: Catarina Hioe – Icahn School of Medicine, Mount Sinai
    Vaccines and Immunotherapy (VAC)
  • Thursday, Apr 16th
    5:00 PM - 5:15 PM US ET
    Imprinted antibody lineages can persist for half a century and dominate cross-neutralizing recall responses to poliovirus
    Location: 102
    Author: Jason Lavinder, PhD – University of Texas, Austin
    Vaccines and Immunotherapy (VAC)
  • Friday, Apr 17th
    12:45 PM - 1:00 PM US ET
    Liver sinusoid constraints make random search of CD8 T cells for Plasmodium parasites efficient
    Location: 104AB
    Author: Vitaly V. Ganusov, PhD (he/him/his) – Texas Biomed. Res. Inst.
    Vaccines and Immunotherapy (VAC)
  • Friday, Apr 17th
    1:00 PM - 1:15 PM US ET
    Allogeneic Tissue Tregs Improve Disease Outcome in Models of Acute Lung and Kidney Injury
    Location: 104AB
    Author: Payam Zarin, PhD (he/him/his) – GentiBio
    Vaccines and Immunotherapy (VAC)
  • Friday, Apr 17th
    1:30 PM - 1:45 PM US ET
    Tissue-Resident Memory B cells Mediate Local and Metastatic anti-Cancer Immunity
    Location: 104AB
    Vaccines and Immunotherapy (VAC)
  • Friday, Apr 17th
    1:45 PM - 2:00 PM US ET
    Structural Insights and Immunogenic Enhancement of KRAS Neoantigen Recognition by TCRs in Cancer Immunotherapy
    Location: 104AB
    Author: Bassant Y. Eldaly (she/her/hers) – Univ. of Notre Dame
    Vaccines and Immunotherapy (VAC)
  • Friday, Apr 17th
    2:00 PM - 2:15 PM US ET
    A Novel Hybrid Biological-Biomaterial Vector for Antigen Delivery and Human Dendritic Cell Maturation
    Location: 104AB
    Author: Gavin Twoey, BS (he/him/his) – Roswell Park Comp. Cancer Ctr.
    Vaccines and Immunotherapy (VAC)
  • Saturday, Apr 18th
    9:45 AM - 10:00 AM US ET
    The Immune Signatures Data Resource 2.0: An Expanded Compendium of Systems Vaccinology Datasets
    Location: 157
    Author: Jian Xing – Yale School of Medicine
    Vaccines and Immunotherapy (VAC)
  • Saturday, Apr 18th
    10:00 AM - 10:15 AM US ET
    In vitro modeling for the in-depth characterization of mRNA vaccines
    Location: 157
    Author: David Forgacs, PhD – Sanofi US
    Vaccines and Immunotherapy (VAC)
  • Saturday, Apr 18th
    10:15 AM - 10:30 AM US ET
    Clinical correlates of maternal antibody interference with oral rotavirus vaccine immunogenicity
    Location: 157
    Vaccines and Immunotherapy (VAC)
  • Saturday, Apr 18th
    10:30 AM - 10:45 AM US ET
    Human Spleen Organoids as a Preclinical Platform for Evaluating Vaccine-Induced Antibody Responses
    Location: 157
    Author: Okikiola Olajide, PhD (she/her/hers) – Stanford Univ.
    Vaccines and Immunotherapy (VAC)
  • Saturday, Apr 18th
    10:45 AM - 11:00 AM US ET
    Distinct Inflammatory Programs Underlie the Intramuscular Lipid Nanoparticle Response
    Location: 157
    Author: Will Dowell – University of Vermont
    Vaccines and Immunotherapy (VAC)
  • Saturday, Apr 18th
    11:00 AM - 11:15 AM US ET
    Vaccine-induced Immunometabolic Reprogramming in Neonates from The Gambia and Papua New Guinea
    Location: 157
    Author: Utsa Bhaduri – Harvard Medical School, Boston Children's Hospital
    Vaccines and Immunotherapy (VAC)
  • Sunday, Apr 19th
    9:45 AM - 10:00 AM US ET
    A novel double-stranded RNA adjuvant markedly amplifies the immunogenicity of nucleoside-modified mRNA-LNP vaccines
    Location: 102
    Author: Fernanda C. Coirada, PhD (she/her/hers) – University of Pennsylvania
    Vaccines and Immunotherapy (VAC)
  • Sunday, Apr 19th
    10:00 AM - 10:15 AM US ET
    Bioactive Enhanced Adjuvant Chemokine Oligonucleotide Nanoparticles (BEACON) for Mucosal Vaccination Against Genital Herpes
    Location: 102
    Author: Sachin Bhagchandani, PhD – Yale School of Medicine
    Vaccines and Immunotherapy (VAC)
  • Sunday, Apr 19th
    10:15 AM - 10:30 AM US ET
    IL-15 induces durable resident memory T cell formation and function following genetically attenuated Plasmodium vaccination in mice
    Location: 102
    Author: Rizwan M. Mahmud, MS (he/him/his) – University of Minnesota, Twin Cities
    Vaccines and Immunotherapy (VAC)
  • Sunday, Apr 19th
    10:30 AM - 10:45 AM US ET
    Optimizing T Cell Priming Using TLR4/9 Combination Adjuvant For Robust Cell-Mediated Immunity Against Influenza
    Location: 102
    Author: Dan Nguyen (she/her/hers) – Univ. of California, Irvine
    Vaccines and Immunotherapy (VAC)
  • Sunday, Apr 19th
    10:45 AM - 11:00 AM US ET
    The roles of Type I interferon subtypes and signaling in mRNA lipid nanoparticle vaccine-induced CD8 T-cell protective immunity.
    Location: 102
    Author: Samita Kafle, PhD (she/her/hers) – Thomas Jefferson Univ.
    Vaccines and Immunotherapy (VAC)
  • Sunday, Apr 19th
    11:00 AM - 11:15 AM US ET
    Type 1 Interferon Restricts mRNA Vaccine Efficacy Through Suppression of Antigen Uptake in Conventional Dendritic Cells
    Location: 102
    Author: Tyson Lobb – Saint Louis University School of Medicine
    Vaccines and Immunotherapy (VAC)